U.S. regulators and lawmakers recently helped advance what one generic drug industry leader coined “the most important pharmaceutical legislation since the 1984 Hatch-Waxman Act”: a plan that could help employers get a better handle on rising health care costs.

The House of Representatives has approved historic user fee proposals negotiated by the pharmaceutical industry and the Food and Drug Administration for generic drugs and biosimilar products.

Register or login for access to this item and much more

All Employee Benefit News content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access